ECE2018 ePoster Presentations Pituitary and Neuroendocrinology (36 abstracts)
GSP gene mutation in a sample of Iraqi acromegalic patients and their response to long-acting repeatable octerotide
Abbas Rahmah 1 , Assel Sami 2 & Wathiq Abbas 2
1National Diabetic Center, Baghdad, Iraq; 2Genetic Engineering and Biotechnology Institute, Baghdad, Iraq.
Patients and methods: 190 acromegalic patients are registered in the National Diabetes Center, 60 were enrolled in the study. They were randomly selected by simple sampling technique according to their scheduled visits monthly to receive - long acting repeatable octreotide injections (LAR).
Results:
| All subjects | Males | Females | |
| Number | 60 | 32 | 28 |
| Age (mean ± SD) years | 46.35±10.81 | 46.3±10.9 | 46.3±10.8 |
| Duration (mean ± SD) years | 10.44±6.5 | 10.5±6.7 | 10.4±6.5 |
| Minimum duration years | 1 month | 6 month | 1 month |
| Maximum years | 30 years | 30 years | 20 years |
| Patients with mutation | Patients without mutation | P-Value | |
| Number | 28 | 32 | |
| Males number (%) | 14 (50%) | 18 (56.25%) | 0.7293 |
| Females number (%) | 14 (50%) | 14 (43.75%) | 0.7449 |
| Macroadenoma | 22 (78.5%) | 25 (78.12%) | 0.9751 |
| Microadenoma | 6 (21%) | 7 (21.87%) | 0.9708 |
| Trans-sphenoidal hypohysectomy | 8 (28.5%) | 15 (46.87%) | 0.4031 |
| No hypophysectomy | 20 (71.4%) | 17 (53.12%) | 0.2576 |
| Patient with no mutation | Patient with mutation | P-value | ||
| Number | 32 | 28 | ||
| Response | Full responder | 18 (56.25%) | 14 (50%) | 0.7293 |
| Partial responders | 12 (37.5%) | 7 (25%) | 0.5872 | |
| Non responders | 2 (6.25%) | 7 (25%) | 0.5861 |
| Patient with A mutation | Patient with non mutation | P-value | ||
| Number | 20 | 8 | ||
| Response | Full responder | 8 (40%) | 6 (75%) | 0.2094 |
| Partial responders | 6 (30%) | 1 (21.5%) | 0.8722 | |
| Non responders | 6 (30%) | 1 (21.5%) | 0.8722 |
| Mutation A | Non A mutation | P-value | |
| Number | 20 | 8 | |
| Males number (%) | 10 (50%) | 4 (50%) | 1.0000 |
| Females number (%) | 10 (50%) | 4 (50%) | 1.0000 |
| Macroadenoma | 16 (80%) | 6 (75%) | 1.8034 |
| Microadenoma | 4 (20%) | 2 (25%) | 0.8982 |
| Hypohysectomy | 7 (35%) | 1 (12.5%) | 0.6735 |
| No hypophysectomy | 13 (65%) | 7 (87%) | 0.3046 |
Conclusion: The gold – standard therapy for acromegaly, there is a role for medical treatment by somatostatin analogues as long-acting octreotide (LAR). The response to LAR was found to be affected by gsp gene mutation on chromosome 20 in a sample of Iraqi acromegalic patients. gsp gene mutation was found to reduce the response to LAR versus those with no mutation, however deletion of cystine in codon 196 of exon 8 was found to be favorable by increasing the percentage of full respondents to LAR versus other types of mutation.
Article tools
My recent searches
My recently viewed abstracts
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more